http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 02 Jul 2026 08:17:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Elicio+Therapeutics%2C+++++++++++++++++/26724301.html si-local-file:///var/storage/secattach/20260702/26724301.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Elicio+Therapeutics%2C+++++++++++++++++/26724301.html Thu, 02 Jul 2026 08:17:00 -0400 ELTX O.31966703 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Elicio+Therapeutics%2C+++++++++++++++++/26724301.html si-local-file:///var/storage/secattach/20260702/26724301.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Elicio+Therapeutics%2C+++++++++++++++++/26724301.html Thu, 02 Jul 2026 08:17:00 -0400 ELTX O.31966703 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Elicio+Therapeutics%2C++++++For%3A+Jul+01/26723723.html si-local-file:///var/storage/secattach/20260702/26723723.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Elicio+Therapeutics%2C++++++For%3A+Jul+01/26723723.html Thu, 02 Jul 2026 06:20:00 -0400 ELTX O.31966703 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Elicio+Therapeutics%2C++++++For%3A+Jul+01/26723723.html si-local-file:///var/storage/secattach/20260702/26723723.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Elicio+Therapeutics%2C++++++For%3A+Jul+01/26723723.html Thu, 02 Jul 2026 06:20:00 -0400 ELTX O.31966703 http://www.streetinsider.com/Equity+Offerings/Elicio+Therapeutics+prices+%2415M+registered+direct+offering/26722844.html <p>Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced the pricing of a registered direct offering of 4,380,313 shares of common stock at an aggregate gross proceeds of approximately $15 million, before placement agent fees and other offering expenses.</p> <p>The offering is led by two new institutional investors, with participation from an existing shareholder. Closing is expected on or about July 6, 2026, subject to customary closing conditions.</p> <p>The company said it intends to use net proceeds primarily to fund the planned Phase 1 clinical development of its lead candidate, ELI-002 7P, in metastatic pancreatic ductal adenocarcinoma (PDAC), as well as its broader pipeline and http://www.streetinsider.com/Equity+Offerings/Elicio+Therapeutics+prices+%2415M+registered+direct+offering/26722844.html Thu, 02 Jul 2026 00:25:23 -0400 A.02062790 A.50202486 ELTX O.03096051 O.31966703 O.53171475 http://www.streetinsider.com/Equity+Offerings/Elicio+Therapeutics+prices+%2415M+registered+direct+offering/26722844.html <p>Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced the pricing of a registered direct offering of 4,380,313 shares of common stock at an aggregate gross proceeds of approximately $15 million, before placement agent fees and other offering expenses.</p> <p>The offering is led by two new institutional investors, with participation from an existing shareholder. Closing is expected on or about July 6, 2026, subject to customary closing conditions.</p> <p>The company said it intends to use net proceeds primarily to fund the planned Phase 1 clinical development of its lead candidate, ELI-002 7P, in metastatic pancreatic ductal adenocarcinoma (PDAC), as well as its broader pipeline and http://www.streetinsider.com/Equity+Offerings/Elicio+Therapeutics+prices+%2415M+registered+direct+offering/26722844.html Thu, 02 Jul 2026 00:25:23 -0400 A.02062790 A.50202486 ELTX O.03096051 O.31966703 O.53171475 http://www.streetinsider.com/Equity+Offerings/Elicio+Therapeutics+prices+%2415M+registered+direct+offering/26722844.html <p>Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced the pricing of a registered direct offering of 4,380,313 shares of common stock at an aggregate gross proceeds of approximately $15 million, before placement agent fees and other offering expenses.</p> <p>The offering is led by two new institutional investors, with participation from an existing shareholder. Closing is expected on or about July 6, 2026, subject to customary closing conditions.</p> <p>The company said it intends to use net proceeds primarily to fund the planned Phase 1 clinical development of its lead candidate, ELI-002 7P, in metastatic pancreatic ductal adenocarcinoma (PDAC), as well as its broader pipeline and http://www.streetinsider.com/Equity+Offerings/Elicio+Therapeutics+prices+%2415M+registered+direct+offering/26722844.html Thu, 02 Jul 2026 00:25:23 -0400 A.02062790 A.50202486 ELTX O.03096051 O.31966703 O.53171475 http://www.streetinsider.com/Equity+Offerings/Elicio+Therapeutics+prices+%2415M+registered+direct+offering/26722844.html <p>Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced the pricing of a registered direct offering of 4,380,313 shares of common stock at an aggregate gross proceeds of approximately $15 million, before placement agent fees and other offering expenses.</p> <p>The offering is led by two new institutional investors, with participation from an existing shareholder. Closing is expected on or about July 6, 2026, subject to customary closing conditions.</p> <p>The company said it intends to use net proceeds primarily to fund the planned Phase 1 clinical development of its lead candidate, ELI-002 7P, in metastatic pancreatic ductal adenocarcinoma (PDAC), as well as its broader pipeline and http://www.streetinsider.com/Equity+Offerings/Elicio+Therapeutics+prices+%2415M+registered+direct+offering/26722844.html Thu, 02 Jul 2026 00:25:23 -0400 A.02062790 A.50202486 ELTX O.03096051 O.31966703 O.53171475 http://www.streetinsider.com/Equity+Offerings/Elicio+Therapeutics+prices+%2415M+registered+direct+offering/26722844.html <p>Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced the pricing of a registered direct offering of 4,380,313 shares of common stock at an aggregate gross proceeds of approximately $15 million, before placement agent fees and other offering expenses.</p> <p>The offering is led by two new institutional investors, with participation from an existing shareholder. Closing is expected on or about July 6, 2026, subject to customary closing conditions.</p> <p>The company said it intends to use net proceeds primarily to fund the planned Phase 1 clinical development of its lead candidate, ELI-002 7P, in metastatic pancreatic ductal adenocarcinoma (PDAC), as well as its broader pipeline and http://www.streetinsider.com/Equity+Offerings/Elicio+Therapeutics+prices+%2415M+registered+direct+offering/26722844.html Thu, 02 Jul 2026 00:25:23 -0400 A.02062790 A.50202486 ELTX O.03096051 O.31966703 O.53171475 http://www.streetinsider.com/Equity+Offerings/Elicio+Therapeutics+prices+%2415M+registered+direct+offering/26722844.html <p>Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced the pricing of a registered direct offering of 4,380,313 shares of common stock at an aggregate gross proceeds of approximately $15 million, before placement agent fees and other offering expenses.</p> <p>The offering is led by two new institutional investors, with participation from an existing shareholder. Closing is expected on or about July 6, 2026, subject to customary closing conditions.</p> <p>The company said it intends to use net proceeds primarily to fund the planned Phase 1 clinical development of its lead candidate, ELI-002 7P, in metastatic pancreatic ductal adenocarcinoma (PDAC), as well as its broader pipeline and http://www.streetinsider.com/Equity+Offerings/Elicio+Therapeutics+prices+%2415M+registered+direct+offering/26722844.html Thu, 02 Jul 2026 00:25:23 -0400 A.02062790 A.50202486 ELTX O.03096051 O.31966703 O.53171475 http://www.streetinsider.com/Press+Releases/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html <p>BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- <strong>Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), </strong>a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock pursuant to a registered direct offering (the “Offering”). The Offering is expected to result in gross proceeds of approximately $15 million, before deducting placement agents’ fees and other Offering expenses. The closing of http://www.streetinsider.com/Press+Releases/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html Thu, 02 Jul 2026 00:25:00 -0400 A.02062790 A.50202486 ELTX O.03096051 O.31966703 O.53171475 http://www.streetinsider.com/Press+Releases/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html <p>BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- <strong>Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), </strong>a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock pursuant to a registered direct offering (the “Offering”). The Offering is expected to result in gross proceeds of approximately $15 million, before deducting placement agents’ fees and other Offering expenses. The closing of http://www.streetinsider.com/Press+Releases/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html Thu, 02 Jul 2026 00:25:00 -0400 A.02062790 A.50202486 ELTX O.03096051 O.31966703 O.53171475 http://www.streetinsider.com/Press+Releases/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html <p>BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- <strong>Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), </strong>a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock pursuant to a registered direct offering (the “Offering”). The Offering is expected to result in gross proceeds of approximately $15 million, before deducting placement agents’ fees and other Offering expenses. The closing of http://www.streetinsider.com/Press+Releases/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html Thu, 02 Jul 2026 00:25:00 -0400 A.02062790 A.50202486 ELTX O.03096051 O.31966703 O.53171475 http://www.streetinsider.com/Press+Releases/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html <p>BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- <strong>Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), </strong>a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock pursuant to a registered direct offering (the “Offering”). The Offering is expected to result in gross proceeds of approximately $15 million, before deducting placement agents’ fees and other Offering expenses. The closing of http://www.streetinsider.com/Press+Releases/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html Thu, 02 Jul 2026 00:25:00 -0400 A.02062790 A.50202486 ELTX O.03096051 O.31966703 O.53171475 http://www.streetinsider.com/Press+Releases/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html <p>BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- <strong>Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), </strong>a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock pursuant to a registered direct offering (the “Offering”). The Offering is expected to result in gross proceeds of approximately $15 million, before deducting placement agents’ fees and other Offering expenses. The closing of http://www.streetinsider.com/Press+Releases/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html Thu, 02 Jul 2026 00:25:00 -0400 A.02062790 A.50202486 ELTX O.03096051 O.31966703 O.53171475 http://www.streetinsider.com/Press+Releases/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html <p>BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- <strong>Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), </strong>a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock pursuant to a registered direct offering (the “Offering”). The Offering is expected to result in gross proceeds of approximately $15 million, before deducting placement agents’ fees and other Offering expenses. The closing of http://www.streetinsider.com/Press+Releases/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html Thu, 02 Jul 2026 00:25:00 -0400 A.02062790 A.50202486 ELTX O.03096051 O.31966703 O.53171475 http://www.streetinsider.com/Globe+Newswire/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html <p>BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- <strong>Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), </strong>a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock pursuant to a registered direct offering (the “Offering”). The Offering is expected to result in gross proceeds of approximately $15 million, before deducting placement agents’ fees and other Offering expenses. The closing of http://www.streetinsider.com/Globe+Newswire/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html Thu, 02 Jul 2026 00:25:00 -0400 A.02062790 A.50202486 ELTX O.03096051 O.31966703 O.53171475 http://www.streetinsider.com/Globe+Newswire/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html <p>BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- <strong>Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), </strong>a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock pursuant to a registered direct offering (the “Offering”). The Offering is expected to result in gross proceeds of approximately $15 million, before deducting placement agents’ fees and other Offering expenses. The closing of http://www.streetinsider.com/Globe+Newswire/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html Thu, 02 Jul 2026 00:25:00 -0400 A.02062790 A.50202486 ELTX O.03096051 O.31966703 O.53171475 http://www.streetinsider.com/Globe+Newswire/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html <p>BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- <strong>Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), </strong>a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock pursuant to a registered direct offering (the “Offering”). The Offering is expected to result in gross proceeds of approximately $15 million, before deducting placement agents’ fees and other Offering expenses. The closing of http://www.streetinsider.com/Globe+Newswire/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html Thu, 02 Jul 2026 00:25:00 -0400 A.02062790 A.50202486 ELTX O.03096051 O.31966703 O.53171475 http://www.streetinsider.com/Globe+Newswire/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html <p>BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- <strong>Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), </strong>a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock pursuant to a registered direct offering (the “Offering”). The Offering is expected to result in gross proceeds of approximately $15 million, before deducting placement agents’ fees and other Offering expenses. The closing of http://www.streetinsider.com/Globe+Newswire/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html Thu, 02 Jul 2026 00:25:00 -0400 A.02062790 A.50202486 ELTX O.03096051 O.31966703 O.53171475 http://www.streetinsider.com/Globe+Newswire/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html <p>BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- <strong>Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), </strong>a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock pursuant to a registered direct offering (the “Offering”). The Offering is expected to result in gross proceeds of approximately $15 million, before deducting placement agents’ fees and other Offering expenses. The closing of http://www.streetinsider.com/Globe+Newswire/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html Thu, 02 Jul 2026 00:25:00 -0400 A.02062790 A.50202486 ELTX O.03096051 O.31966703 O.53171475 http://www.streetinsider.com/Globe+Newswire/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html <p>BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- <strong>Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), </strong>a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock pursuant to a registered direct offering (the “Offering”). The Offering is expected to result in gross proceeds of approximately $15 million, before deducting placement agents’ fees and other Offering expenses. The closing of http://www.streetinsider.com/Globe+Newswire/Elicio+Therapeutics+Announces+Pricing+of+%2415+Million+Registered+Direct+Offering/26722843.html Thu, 02 Jul 2026 00:25:00 -0400 A.02062790 A.50202486 ELTX O.03096051 O.31966703 O.53171475 http://www.streetinsider.com/Index+Changes/Elicio+Therapeutics+joins+Russell+2000+and+Russell+3000+indexes/26702343.html <p>Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company, was added to the Russell 2000® and Russell 3000® indexes, effective after the U.S. market close on June 26, 2026, as part of the 2026 Russell indexes annual reconstitution, according to a press release from the company.</p> <p>The Russell 3000® Index tracks the performance of the largest 3,000 publicly traded U.S. companies and serves as a broad benchmark for the U.S. equity market. The Russell 2000® Index, a subset of the Russell 3000®, measures the performance of small-cap stocks and represents approximately 10% of the total market capitalization of the U.S. equity http://www.streetinsider.com/Index+Changes/Elicio+Therapeutics+joins+Russell+2000+and+Russell+3000+indexes/26702343.html Mon, 29 Jun 2026 08:00:36 -0400 ELTX http://www.streetinsider.com/Press+Releases/Elicio+Therapeutics+Added+to+Russell+2000%C2%AE+and+Russell+3000%C2%AE+Indexes/26702243.html <p>BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company was added to the Russell 2000^® and Russell 3000^® Indexes, effective after the U.S. market close on June 26, 2026, as part of the 2026 Russell indexes annual reconstitution.</p> <p>“Inclusion of Elicio Therapeutics in the Russell 2000^® and Russell 3000^® Indexes is a meaningful milestone that reflects the growing recognition of the Company’s progress,” said Robert Connelly, Chief Executive Officer of Elicio Therapeutics. “As we continue http://www.streetinsider.com/Press+Releases/Elicio+Therapeutics+Added+to+Russell+2000%C2%AE+and+Russell+3000%C2%AE+Indexes/26702243.html Mon, 29 Jun 2026 08:00:00 -0400 ELTX ELTX http://www.streetinsider.com/Press+Releases/Elicio+Therapeutics+Added+to+Russell+2000%C2%AE+and+Russell+3000%C2%AE+Indexes/26702243.html <p>BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company was added to the Russell 2000^® and Russell 3000^® Indexes, effective after the U.S. market close on June 26, 2026, as part of the 2026 Russell indexes annual reconstitution.</p> <p>“Inclusion of Elicio Therapeutics in the Russell 2000^® and Russell 3000^® Indexes is a meaningful milestone that reflects the growing recognition of the Company’s progress,” said Robert Connelly, Chief Executive Officer of Elicio Therapeutics. “As we continue http://www.streetinsider.com/Press+Releases/Elicio+Therapeutics+Added+to+Russell+2000%C2%AE+and+Russell+3000%C2%AE+Indexes/26702243.html Mon, 29 Jun 2026 08:00:00 -0400 ELTX ELTX